These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32711177)

  • 1. Impact of Perfusate Glucose Concentration on Perioperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Lindsey PT; Martin RCG; Scoggins CR; Philips P; Marshall BM; Carter TS; Egger ME
    J Surg Res; 2020 Dec; 256():206-211. PubMed ID: 32711177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study.
    Feng F; Gao Q; Wu Y; Liu C; Yu Y; Li B; Chu K; Yi B; Cheng Q; Jiang X
    Eur J Surg Oncol; 2021 Sep; 47(9):2363-2368. PubMed ID: 34119376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Kubi B; Gunn J; Fackche N; Cloyd JM; Abdel-Misih S; Grotz T; Leiting J; Fournier K; Lee AJ; Dineen S; Dessureault S; Veerapong J; Baumgartner JM; Clarke C; Mogal H; Patel SH; Dhar V; Lambert L; Hendrix RJ; Abbott DE; Pokrzywa C; Raoof M; Lee B; Maithel SK; Staley CA; Johnston FM; Wang NY; Greer JB
    J Surg Res; 2020 Nov; 255():475-485. PubMed ID: 32622162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre.
    Keyes AM; Kelly ME; McInerney N; Khan MF; Bolger JC; McCormack E; Grundy J; McCormack O; MacHale J; Conneely J; Brennan D; Cahill R; Shields C; Moran B; Mulsow J
    Eur J Surg Oncol; 2021 Sep; 47(9):2358-2362. PubMed ID: 33895028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and predictive value of blood lactate levels during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a comparative analysis.
    Tonello M; Barina A; Turchet F; De Simoni O; Alfieri R; Franzato B; Gruppo M; Dengo B; Deffenu D; Di Pasquale D; Fiore T; Pietropaoli C; Munaron S; Zanardo G; Sommariva A; Pilati P
    Updates Surg; 2021 Feb; 73(1):313-319. PubMed ID: 33146888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 12. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastomotic leakage following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A clinical cohort study.
    Herzberg J; Acs M; Guraya SY; Schlitt HJ; Honarpisheh H; Strate T; Piso P
    Surg Oncol; 2024 Jun; 54():102080. PubMed ID: 38663060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Outcomes After Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Gani F; Conca-Cheng AM; Nettles B; Ahuja N; Johnston FM
    J Surg Res; 2019 Feb; 234():240-248. PubMed ID: 30527480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis: Improved Short-term Outcomes Revealed Through Propensity Score Matching Analysis.
    Bortoli N; Tonello M; Pizzolato E; Cenzi C; Pilati P; Sommariva A
    J Gastrointest Cancer; 2024 Jun; 55(2):733-739. PubMed ID: 38224418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dextrose-Containing Carrier Solution for Hyperthermic Intraperitoneal Chemotherapy: Increased Intraoperative Hyperglycemia and Postoperative Complications.
    Torphy RJ; Stewart C; Sharma P; Halpern AL; Oase K; Herter W; Bartsch C; Friedman C; Del Chiaro M; Schulick RD; Gleisner A; McCarter MD; Ahrendt SA
    Ann Surg Oncol; 2020 Dec; 27(13):4874-4882. PubMed ID: 32306237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
    Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
    J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Doxorubicin for 90 Minutes
    Acs M; Halmy L; Isgandarova S; Blaj S; Gerken M; Hormann B; Piso P
    Anticancer Res; 2022 Feb; 42(2):1019-1029. PubMed ID: 35093903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcome of Icelandic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) abroad].
    Petursdottir A; Gunnarsson O; Valsdottir EB
    Laeknabladid; 2020 Jul; 106(7):344-348. PubMed ID: 32608356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.